LCB 03-0110, a Novel Pan-Discoidin Domain Receptor/c-Src Family Tyrosine Kinase Inhibitor, Suppresses Scar Formation by Inhibiting Fibroblast and Macrophage Activation
Authors:
- Trong Nhat PhanTPTrong Nhat Phan
- Seung Hee JungSJSeung Hee Jung
- Sun Young KimSKSun Young Kim
- Jong Un ChoJCJong Un Cho
- Hyangsook LeeHLHyangsook Lee
- Sung Ho WooSWSung Ho Woo
- Tae Kyo ParkTPTae Kyo Park
- Beom-Seok YangBYBeom-Seok Yang
- 1 March 2012
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 340 (3) , 510-519
Abstract
Wound healing generally induces an inflammatory response associated with tissue fibrosis in which activated macrophage and myofibroblast cells are primarily involved. Although this is known to be the underlying mechanism for scarring and various fibrotic pathologies, no effective intervention is currently available. We identified (3-(2-(3-(morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol (LCB 03-0110), a thienopyridine derivative, as a potent inhibitor of discoidin domain receptor family tyrosine kinases and discovered that this compound strongly inhibits several tyrosine kinases, including the c-Src family, spleen tyrosine kinase, Bruton9s tyrosine kinase, and vascular endothelial growth factor receptor 2, which are important for immune cell signaling and inflammatory reactions. LCB 03-0110 suppressed the proliferation and migration of primary dermal fibroblasts induced by transforming growth factor β1 and type I collagen, and this result correlated with the inhibition ability of the compound against enhanced expression of α-smooth muscle actin and activation of Akt1 and focal adhesion kinase. In J774A.1 macrophage cells activated by lipopolysaccharide LCB 03-0110 inhibited cell migration and nitric oxide, inducible nitric-oxide synthase, cyclooxygenase 2, and tumor necrosis factor-α synthesis. LCB 03-0110 applied topically to full excisional wounds on rabbit ears suppressed the accumulation of myofibroblast and macrophage cells in the healing wound and reduced hypertrophic scar formation after wound closing, without delaying the wound closing process. Taken together, the pharmacological activities of LCB 03-0110 suggest that it could be an effective agent for suppressing fibroinflammation by simultaneously targeting activated fibroblasts and macrophages.Keywords
This publication has 44 references indexed in Scilit:
- Discoidin domain receptor 2 is a critical regulator of epithelial–mesenchymal transitionMatrix Biology, 2011
- Primary B Cell Immunodeficiencies: Comparisons and ContrastsAnnual Review of Immunology, 2009
- Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferationBlood, 2008
- Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarringJournal of Experimental Medicine, 2008
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences, 2007
- Discoidin Domain Receptor 1 Null Mice Are Protected against Hypertension-Induced Renal DiseaseJournal of the American Society of Nephrology, 2006
- Wound Healing in the PU.1 Null Mouse—Tissue Repair Is Not Dependent on Inflammatory CellsCurrent Biology, 2003
- Beta 2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils.Journal of Cell Biology, 1994